Assay for detecting genetic abnormalities in genomic nucleic acids

• US 8,093,063 B2
• Filed: 11/29/2007
• Issued: 01/10/2012
• Est. Priority Date: 11/29/2007
• Status: Active Grant

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Albitar, Maher
• Primary Examiner(s): Sisson, Bradley L
• Application Number:
  US11/947,056
• Publication Number:
  US 20090142755A1
• Time in Patent Office: 1,503 Days
• Field of Search: None
• US Class Current: 436/94
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 2565/518 characterised by the immobilisation of the nucleic acid sample or target
• CPC Class Codes: C12Q 2565/626 being a flow cytometer
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The present invention provides methods of detecting unamplifed genomic nucleic acid anchored to a solid support. The methods are useful for the detecting genetic abnormalities associated with various diseases, diagnosis, and prognosis.

Claims

1. A method for detecting a target sequence in genomic nucleic acid, comprising:

a. contacting a sample of genomic nucleic acid comprising said target sequence with a probe specific for said target sequence to form a complex comprising said genomic nucleic acid and said probe hybridized to said target sequence, wherein said probe comprises a detectable label, and said target sequence has not been amplified;

b. anchoring on a solid support said complex formed in step (a) through said genomic nucleic acid by means other than nucleic acid hybridization; and

c. detecting the presence of said target sequence in said genomic nucleic acid by detecting association of said label with said solid support.

2. The method of claim 1, wherein said solid support comprises a first member of a binding pair and said genomic nucleic acid comprises a second member of the binding pair, and wherein binding of the binding pair members anchor said genomic nucleic acid to said solid support.

3. A method of claim 1, wherein said genomic nucleic acid is anchored covalently to said solid support.

4. The method of claim 1, wherein said solid support is a bead, a microwell plate, or a glass surface.

5. The method of claim 2, wherein said binding pair is a ligand-receptor, a hormone-receptor, or an antigen-antibody.

6. The method of claim 2, wherein said binding pair is biotin and streptavidin or variants of streptavidin.

7. The method of claim 1, wherein said probe is an oligonucleotide, an artificial chromosome, a fragmented artificial chromosome, a genomic DNA, an RNA, or a peptide nucleic acid.

8. A method of claim 1, wherein the length of the probe is at least 50 nucleotides.

9. The method of claim 1, wherein the detectable label is a fluorophore, nanoparticle, isotope, chemiluminiscent compound, enzyme, or hapten.

10. The method of claim 1, wherein said complex is detected on the solid support by flow cytometry.

11. The method of claim 1, wherein said complex is detected by detecting a labeled reagent that binds to the detectable label of the probe.

12. The method of claim 11, wherein said labeled reagent is a labeled antibody that is specific for the detectable label.

13. The method of claim 1, wherein said genomic nucleic acid is present in a test sample, and wherein said test sample is cells, tissues, body fluids, stool, paraffin embedded tissues, cell lysates, or tissue lysates.

14. A method for determining the presence or absence of a genetic abnormality in genomic nucleic acid, comprising:

a. contacting a sample of genomic nucleic acid with a probe specific for said genetic abnormality to form a complex comprising said genomic nucleic acid hybridized to said probe if said genetic abnormality is present in said genomic nucleic acid, wherein said probe comprises a detectable label and said target sequence has not been amplified;

b. anchoring on a solid support said complex formed in step (a) through said genomic nucleic acid by means other than nucleic acid hybridization; and

c. determining the presence or absence of said genetic abnormality wherein detecting an association of said label with said solid support indicates the presence of said genetic abnormality, and wherein detecting no association of said label with said solid support indicates the absence of said genetic abnormality.

15. The method in claim 14, wherein said genetic abnormality is a chromosomal translocation, and first portion of said probe hybridizes to a region of a first chromosome of the translocation, and a second portion of said probe hybridizes to a region of a second chromosome of the translocation.

16. The method in claim 14, wherein the genetic abnormality is a duplication or deletion associated with a particular chromosomal segment or gene.

17. The method of claim 14, wherein said solid support comprises a first member of a binding pair and said genomic nucleic acid comprises a second member of the binding pair, and wherein binding of the binding pair members anchor said genomic nucleic acid to said solid support.

18. A method of claim 14, wherein said genomic nucleic acid is anchored covalently to the solid support.

19. The method of claim 14, wherein said genomic nucleic acid is genomic DNA.

20. The method of claim 14, wherein said solid support is a bead, a microwell plate, or a glass surface.

21. The method of claim 14, wherein said binding pair is a ligand-receptor, a hormone-receptor, or an antigen-antibody.

22. The method of claim 14, wherein said binding pair is biotin and streptavidin or variants of streptavidin.

23. The method of claim 14, wherein said probe is an oligonucleotide, an artificial chromosome, a fragmented artificial chromosome, a genomic DNA, an RNA, or a peptide nucleic acid.

24. A method of claim 14, wherein the length of the probe is at least 50 nucleotides.

25. The method of claim 14, wherein the probe is labeled with a fluorophore, nanoparticle, isotope, chemiluminiscent compound, enzyme, or hapten.

26. The method of claim 14, wherein said complex is detected on the solid support by flow cytometry.

27. The method of claim 14, wherein said complex is detected by detecting a labeled reagent that binds to the detectable label of the probe.

28. The method of claim 27, wherein said labeled reagent is a labeled antibody that is specific for the detectable label.

29. The method of claim 14, wherein said genomic nucleic acid is present in a test sample, and wherein said test sample is cells, tissues, body fluids, stool, paraffin embedded tissues, cell lysates, or tissue lysates.

30. A method for determining the presence or absence of a genetic abnormality in genomic nucleic acid, comprising:

a. contacting a sample of genomic nucleic acid with a first probe specific for said genetic abnormality to form a first complex comprising said genomic nucleic acid hybridized to said first probe, if said genetic abnormality is present, wherein said probe comprises a detectable label, said genomic nucleic acid has not been amplified;

b. anchoring on a solid support said complex formed in step (a) through said genomic nucleic acid by means other than nucleic acid hybridization;

c. contacting a reference nucleic acid with a second probe specific for said reference nucleic acid to form a second complex comprising said reference nucleic acid hybridized to said second probe, wherein said second probe comprises a detectable label;

d. anchoring on a solid support said complex formed in step (c) through said reference nucleic acid by means other than nucleic acid hybridization; and

e. measuring the amount of said first complex formed by detecting the detectable label of said first probe associated with the complex and measuring the amount of second complex formed by detecting the detectable label of said second probe associated with the complex; and

f. comparing the amount of said first complex to the amount of said second complex, wherein a difference in the amount of two complexes is an indicative of the absence of said genetic abnormality and a lack of a difference in the amount of two complexes is an indicative of the presence of said genetic abnormality.

31. The method of claim 30, wherein said reference nucleic acid is a house keeping gene or a single copy sequence in the chromosome.

32. The method of claim 30, wherein said genomic nucleic acid and said reference nucleic acid are obtained from the same sample.

33. The method of claim 32, wherein the detectable label of said first probe and said second probe are different.

34. The method of claim 30, wherein said genomic nucleic acid and said reference nucleic acid are obtained from different samples.

35. The method of claim 30, wherein the detectable label of said first probe and said second probe are different.

36. The method of claim 30, wherein said first probe and said second probe are same, and wherein said genomic nucleic acid and said reference nucleic acid are obtained from different samples.

37. A method for determining the presence or absence of a genetic abnormality in genomic nucleic acid, comprising:

a. contacting a sample of genomic nucleic acid with a first probe specific for the genetic abnormality to form a first complex comprising said genomic nucleic acid hybridized to said first probe, if said genetic abnormality is present, wherein said probe comprises a detectable label and said genomic nucleic acid has not been amplified;

b. anchoring on a solid support said first complex formed in step (a) through said genomic nucleic acid by means other than nucleic acid hybridization;

c. contacting said sample of genomic nucleic acid with a second probe specific for a reference nucleic acid to form a second complex comprising said reference nucleic acid hybridized to the second probe, wherein said second probe comprises a detectable label;

d. anchoring on a solid support said second complex formed in step (c) through said genomic nucleic acid by means other than nucleic acid hybridization;

e. measuring the amount of said first complex formed by detecting the detectable label of said first probe associated with the complex and measuring the amount of second complex formed by detecting the detectable label of said second probe associated with the complex;

f. obtaining a ratio of the amount of said first and said second complex; and

g. comparing said ratio obtained to a ratio similarly obtained using genomic nucleic acid from a reference sample, wherein a difference in the ratio is indicative of the presence of said genetic abnormality and a lack of a difference in the amount of two complexes is an indicative of the absence of said genetic abnormality.

38. The method in claim 37, wherein the genetic abnormality is a duplication or deletion associated with a particular chromosomal segment or gene.

39. The method of claim 37, wherein said first complex and second complex are detected on said solid support by flow cytometry.

40. The method of claim 37, wherein the length of said first probe or said second probe is at least 50 nucleotides.

41. The method of claim 37, wherein said solid support consist of a first member of a binding pair and said genomic nucleic acid consist of a second member of the binding pair, and wherein binding of the binding pair members anchor said genomic nucleic acid to said solid support.

42. The method of claim 41, wherein said binding pair is biotin and streptavidin or variants of streptavidin.

43. The method of claim 37, wherein said genomic nucleic acid is genomic DNA.

44. The method of claim 37, wherein said reference nucleic acid is a house keeping gene or a single copy sequence in a chromosome.

45. A method of diagnosis of a disease in an individual, comprising,

a. contacting a sample of genomic nucleic acid from the individual with a probe complementary to nucleic acid sequence specific for said disease to form a complex comprising said genomic nucleic acid and said probe if said genomic nucleic acid contains the nucleic acid sequence specific for said disease, wherein said probe comprises a detectable label and said target sequence of said genomic nucleic acid has not been amplified;

b. anchoring on a solid support said complex formed in step (a) through said genomic nucleic acid by means other than nucleic acid hybridization;

c. measuring the amount of said complex formed on said solid support by detecting the amount of detectable label associated with said support; and

d. comparing the amount of complex formed to the amount of complex formed using genomic nucleic acid from a reference sample assayed under similar conditions, wherein a difference in amount of complex formed from the said individual as compared to the reference sample is diagnostic for said disease.

46. The method of claim 45, wherein said reference sample is taken from a normal individual.

47. The method of claim 45, wherein the method is used for measuring the tumor burden in an individual suspected of having cancer.

48. The method of claim 45, wherein said reference sample is obtained from the same individual after obtaining the test sample.